Specification:150mg/12.5mg×14 tabletsInications:This fixed-dose combination preparation is indicated for: Treatment of essential hypertension.specifically indicated for patients whose blood pressure remains uncontrolled on irbesartan or hydrochlorothiazide monotherapy
CPHI制藥在線為您找到Irbesartan and Hydrochlorthiazide Tablets 價格、Irbesartan and Hydrochlorthiazide Tablets 詳細參數(shù)、Irbesartan and Hydrochlorthiazide Tablets 相關產品、Irbesartan and Hydrochlorthiazide Tablets 供應商等信息，想了解當前Irbesartan and Hydrochlorthiazide Tablets 最新報價，請聯(lián)系江蘇萬高藥業(yè)股份有限公司。
2006-2025 上海博華國際展覽有限公司版權所有（保留一切權利）
滬ICP備05034851號-57
